SEARCH

Current Edition

Gilead

Gilead, following Merck, hits its own safety setback in HIV

The clinical hold comes at an inopportune time for Gilead. Last month, the company’s longtime rival Merck & Co. disclosed worrisome findings from a study …

Continue Reading →
active ingredient

A worrisome safety signal slows Merck’s HIV ambitions

Currently, the world’s best-selling HIV medications are made up of at least three “active ingredients.” But recent years have seen increasing interest in treatments that …

Continue Reading →